Andrew Fein

Takeaways On Unity Biotech's Clinical Data From A Bull Analyst

5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing

Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment

5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing

Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment

After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A Target

Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation

After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A Target

Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation

Analyst: DBV's Peanut Allergy Drug Could Outscore Aimmune's On Safety Front

'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis

Andrew Fein Recent News

Analysts Laud Biogen's M&A Strategy Following Deal to Buy Gene Therapy Company Nightstar

Analyst: NeuroMetrix Benefits From Alternative Pain Management Trend

What Analysts Have To Say About Insmed Following Arikayce Approval

H.C. Wainwright: Acadia Is More Than A One-Trick Pony

Analyst Says Axovant's Bull Case Is Effectively Over

Concert Pharma Shares Rally Over $15 Level Following New Buy Rating, $20 Price Target

Rigorous Trial Design, Nice Risk/Reward Keep Analyst Anxious For Avoxant's Phase 3 MINDSET Data

Looking For Leftover Value in Nivalis Following Drug Trial Miss

Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects

Vertex Pharmaceuticals Relapses To A Neutral Rating At H.C. Wainwright

TG Therapeutics Pulling Off The Band-Aid To Keep GENUINE Cancer Study On Track

'Kadmon Offers A Diverse Clinical Pipeline, And Value Optionality,' H.C. Wainwright Says

H.C. Wainwright Downgrades United Therapeutics To Neutral

H.C. Wainwright Triples Celator Valuation, Says Latest Trial Win Is Rare

Vertex Pharma Is 'Hyped,' H.C. Wainwright Sees 35% Downside

Threshold Pharmaceuticals, Inc. Shares Jump Amid H.C. Wainwright Initiation

UPDATE: H.C. Wainwright & Co. Initiates Coverage On Epizyme, Transition Therapeutics

Analyst Concerns On Vertex's Approved Drug

UPDATE: H.C. Wainwright Initiates Coverage on PharmAthene